Neurogen Biomarking Unveils At-Home Alzheimer's Testing
Neurogen Biomarking is set to revolutionize Alzheimer's disease detection with its groundbreaking at-home p-tau 217 blood test. This novel approach will be highlighted at an esteemed conference, paving the way for innovative healthcare solutions. Chief Scientific Officer, Elisabeth Thijssen, PhD, will present vital findings related to this study, which seeks to validate remote collection of pivotal blood biomarkers.
Highlights of the Conference Presentation
The upcoming session featuring Neurogen will stand out in the Alzheimer's Association International Conference (AAIC), showcasing transformative research outcomes. The session is part of the Featured Research Session (FRS), emphasizing innovative studies that significantly affect dementia diagnosis and care.
Presentation Details
Important aspects of Neurogen's presentation include:
- Date/Time: Scheduled for a Monday session with an engaging podium presentation.
- Format: Followed by an interactive question and answer segment.
- Scientific Session: Focused on Remote Collection of Blood Biomarkers for Alzheimer’s.
- Presenter: Elisabeth Thijssen, PhD, leading the discussion.
- Location: Hall F, where attendees can engage with the findings.
The Vision of Neurogen
Neurogen Biomarking aims to ensure equitable access to essential brain health care. This organization has pioneered the at-home blood biomarker test for phosphorylated (p-tau217), employing proprietary blood collection methods paired with advanced digital cognitive assessments. The results, overseen by board-certified neurologists via telehealth, signify a major leap towards proactive measures in brain health.
Guiding Innovations from Experts
Founded by celebrated neurologist Dr. Rany Aburashed, Neurogen is supported by a team of esteemed brain health specialists. Their collective vision emphasizes delivering actionable insights and accessible technology to enhance early detection and care of Mild Cognitive Impairment (MCI) and dementia linked to Alzheimer's disease.
Contact for More Information
For further inquiries and details about the upcoming presentation, interested parties can reach out to Neurogen Biomarking. They are committed to advancing Alzheimer's research and empowering patients through innovation.
Frequently Asked Questions
1. What is the significance of p-tau 217 testing?
p-tau 217 testing helps in the early identification of Alzheimer’s disease by detecting specific biomarkers in the blood.
2. How does the remote blood collection work?
The remote blood collection utilizes innovative technology that allows individuals to collect samples comfortably and securely at home.
3. What are the implications of this testing for patients?
This testing can lead to timely diagnosis and treatment options, enhancing patient care and supporting families in managing the condition.
4. Who can access the p-tau 217 testing?
Neurogen aims to make this testing accessible to a broad audience, ensuring everyone has the opportunity to monitor their brain health.
5. How can one learn more about Neurogen's offerings?
Visit their official website for more information about services and innovations aimed at improving brain health management.
